Asian Journal of Research and Reports in Endocrinology

Atherogenic Diabetic Dyslipidemia

Dheeraj Kapoor *

Artemis Hospital, Gurugram, Haryana, India.

Ruchi Kapoor

Tata 1mg Technologies Pvt. Ltd., India.

Kunal Jhaveri *

Zydus Lifesciences Limited, Mumbai, India.

*Author to whom correspondence should be addressed.

---

Abstract

Diabetes is a widely prevalent condition and steadily growing as well. In Indian type 2 diabetic patients have a higher amounts of TG and atherogenic lipid sd-LDL. Atherogenic diabetic dyslipidemia is associated with higher residual CV risk and should be treated with a statin as first-line agent. The tendency to develop insulin resistance is a common result of Asian Indians' body composition and dyslipidemia. Diabetic dyslipidemia (DD) is defined by a mild to marked increase in triglyceride-rich lipoproteins, very low-density lipoprotein-cholesterol (VLDL-C) and VLDL-C remnants, and low HDL levels. Along with lifestyle modifications, statins are considered as first-line therapy for diabetic dyslipidemia. Statins have the ability to reduce LDL-C levels by up to 50%. They might improve TG and HDL-C levels further.

Keywords: Diabetes, dyslipidemia, cardiovascular diseases, hypertriglyceridemia, saroglitazar

---

---

---

References

World health organization. Global status report on non-communicable diseases. Chapter 1 – Burden: Mortality, morbidity and risk factors. World health organization; 2010.

International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels,Belgium; 2021.

Available:https://www.diabetesatlas.org

Joshi SR, Anjana RM, Deepa M, Pradeepa R, Bhansali A, Dhandania VK, Joshi PP, Unnikrishnan R, Nirmal E, Subashini R, Madhu SV, Rao PV, Das AK, Kaur T, Shukla DK, Mohan V; ICMR-INDIAB Collaborative Study Group. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study. PLoS One. 2014;9(5):e96808.

Muačević-Katanec D, Reiner Z. Diabetic dyslipidemia or ‘diabetes lipidus’? Expert Rev CardiovascTher. 2011;9(3):341-348.

Arca M, Pigna G, Favoccia C. Mechanisms of diabetic dyslipidemia: Relevance for atherogenesis. Current vascular pharmacology. 2012;10(6):684-6.

Krishnamurthy V, Kerekoppa AR, B, P. Cross-sectional study of pattern of dyslipidemia and prevalence of atherogenic diabetic dyslipidemia in newly detected diabetic patients. Asian Journal of Medical Sciences. 2019;10(6):45–49.

Available:https://doi.org/10.3126/ajms.v10i6.25633

Misra A, Luthra K, Vikram NK. Dyslipidemia in Asian Indians: deteRminants and significance. J Assoc Physicians India; 2004.

Sugden M, Holness M. Pathophysiology of diabetic dyslipidemia: Implications for atherogenesis and treatment. Clinical Lipidology. 2011;6(4):401-11.

Manoria PC, Chopra HK, Parashar SK, et al. The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies. Indian Heart J. 2013;65(6):683–690.

Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008;14(8 Suppl):S3-28.

Nelson AJ, Navar AM, Mulder H, Wojdyla D, Philip S, Granowitz C, Peterson ED, Pagidipati NJ. Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the bypass angioplasty revascularization investigation 2 Diabetes [BARI 2D] Trial). Am J Cardiol. 2020; 132:36-43.

Castañer O, Pintó X, Subirana I, et al. Remnant cholesterol, not LDL-cholesterol, is associated with incident cardiovascular disease. J Am Coll Cardiol. 2020;76:2712-2724

Kannel WB, Vasan RS. Triglycerides as vascular risk factors: New epidemiologic insights for current opinion in cardiology. Curr Opin Cardiol. 2009;24(4):345–350.

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž. ESC/EAS Guidelines for the Management of Dyslipidaemias. European heart journal. 2016;37(39):2999-3058

Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary.2020;26(10):1196-1224.

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1):111-188.

Barakat L, Jayyousi A, Bener A, Zuby B, Zirie M. Comparison of efficacy and safety of rosuvastatin, atorvastatin and pravastatin among dyslipidemic diabetic patients. ISRN Pharmacol. 2013;2013: 146579.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366(9500):1849-61.

Ginsberg HN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses. Diabetes Care. 2011;34Suppl 2:S107-8.

Sosale A, Saboo B, Sosale B. Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: Current evidence. Diabetes Metab Syndr Obes. 2015;8:189-96.

Balakumar P, Rose M, Ganti SS, Krishan P, Singh M. PPAR dual agonists: Are they opening Pandora’s Box? Pharmacol Res. 2007;56(2):91–98.

Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta. 2007; 1771(8):1065-81.

Jain N, Bhansali S, Kurpad AV, et al. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial. Sci Rep. 2019;9(1):19017.

Pai V, Paneerselvam A, Mukhopadhyay S, Bhansali A, Kamath D, Shankar V, Gambhire D, Jani RH, Joshi S, Patel P. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V). Journal of diabetes science and technology. 2014;8(1):132-41.

Jani RH, Pai V, Jha P, Jariwala G, Mukhopadhyay S, Bhansali A, Joshi S. A multicenter, prospective, randomized, double- blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes technology & therapeutics. 2014;16(2):63-71.

Kaul U, Parmar D, Manjunath K, et al. New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovasc Diabetol. 2019;18:80.

Krishnappa Manjunath, Patil Kishor, Sharma Sunil, Jain Payal, Trivedi Purav, Parmar Deven, Patel Pankaj. Effectiveness of The PPAR agonist saroglitazar in nonalcoholic steatohepatitis: Positive data from preclinical & clinical studies; 2020.

Available:10.21203/rs.3.rs-123364/v1

Gluvic Zorana, Tomasevic Ratkoa, Bojovic Ksenijab, Obradovic Milanc, Isenovic Esma R.c,∗. Non-alcoholic fatty liver disease: A multidisciplinary clinical practice approach—the institutional adaptation to existing Clinical Practice Guidelines. Emergency and Critical Care Medicine. 2022;2(1):12-22.

DOI: 10.1097/EC9.0000000000000016